495 -- Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes. | Poliscope

Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.

495

117th Congress

Health

In Committee

Legislative Progress

✓

Introduced

Committee

Floor Vote

Other Chamber

Enacted

Introduced

June 23, 2021

Latest Action

June 24, 2021

Primary Sponsor

Barbara LeeDemocratic(CA)

Momentum (last 30 days)

score

0 actions · 0 new cosponsors · 0 votes

Speed vs cohort

58pct

1d open

vs 1,532 other HRES bills in the 117th — cohort avg 32d

Summary

This resolution recognizes the challenges posed by sickle cell trait and sickle cell disease and encourages relevant screening, research, and surveillance. Sickle cell disease is a group of inherited disorders that cause abnormally shaped red blood cells.

Lobbying filings that explicitly cite this bill (2)

These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.

Filing registrants (1)

VERTEX PHARMACEUTICALS INCORPORATED (2)

VERTEX PHARMACEUTICALS INCORPORATEDclient→VERTEX PHARMACEUTICALS INCORPORATED

2021 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."